Kevin Kelly, Aleksandra Ras, Samantha Helm, Vanessa Spotlow and Honey V Reddi
Solid tumors remain a major health concern with approximately 14 million new cases and 8.2 million cancerrelated deaths per year. Currently multimodality treatment regimens are being explored to make advances against this deadly disease. Tumors are characterized by genomic instability and tailored therapies are being considered based on genetic profiling of cancers, driving precision medicine. This review outlines the various genetic changes present in solid tumors, evaluates the technologies currently used for identification of variants and compares the large panels available for clinical utility and comprehensiveness.
